PERIsign - Prototype for clinical investigation
| Reference number | |
| Coordinator | STB INN AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | May 2022 - December 2023 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 2 spring 2022 |
Important results from the project
** Denna text är maskinöversatt ** The project´s aim has been to take PERIsign from the Proof of Concept phase to a finished prototype approved for clinical trials. During the project, regulatory and technical documentation has been completed and the product is validated before proposal for a clinical trial.
Expected long term effects
** Denna text är maskinöversatt ** The project has contributed to the fact that PERIsign is now very close to a first clinical trial, which is a prerequisite for continued development and market establishment. With the help of the project, we can now evaluate PERIsign on patients in a real hospital environment, which will lead to further knowledge about our product and ensure continued development.
Approach and implementation
We started by setting up requirements specification for PERIsign based on the knowledge we gathered during previous development. After that, the technical development has been carried out iteratively, where a number of prototypes have been developed and evaluated. We are now at the final version to be approved for clinical trial. The project has progressed with good satisfaction, but has been somewhat delayed as we have changed technology suppliers. The change contributed to the delay but was overall a very good decision as the project improved significantly.